Renal Colic (Adult)

Overview

Renal colic describes the acute, severe pain syndrome caused by urinary tract obstruction from calculi (stones) in the renal collecting system or ureter. Despite the term "colic" suggesting intermittent cramping pain, most patients experience constant severe pain with fluctuating intensity superimposed on a steady baseline. [1]

Urolithiasis represents one of the most common urological presentations to emergency departments, affecting approximately 10-15% of the population during their lifetime with significant morbidity, healthcare costs exceeding $10 billion annually in the United States alone, and recurrence rates approaching 50% within 5-10 years after the initial episode. [2] The condition predominantly affects individuals aged 20-60 years, with a historical male predominance (male:female ratio 2:1) that has been narrowing in recent decades due to changing dietary patterns and obesity rates. [2,3]

Early recognition of life-threatening complications—particularly infected obstructing stones (pyonephrosis) and acute kidney injury from bilateral obstruction or obstruction of a solitary kidney—is critical for preventing permanent renal damage and sepsis-related mortality. This guide provides an evidence-based approach to diagnosis, risk stratification, pain management, medical expulsive therapy, and surgical referral indications.

---

Epidemiology

Prevalence and Incidence

The global prevalence of kidney stones has increased substantially over the past four decades. Current lifetime risk estimates range from 10-15% in developed nations, with annual incidence rates of 100-400 per 100,000 population depending on geographic region and climate. [2,3]

Demographics and Risk Factors

Age Distribution

• Peak incidence: 40-60 years
• Increasing pediatric incidence (attributed to dietary changes)
• Uncommon before age 20 or after age 70

Sex Differences The gender gap has narrowed significantly from a 3:1 male predominance to approximately 1.3:1, primarily due to rising obesity rates in women and changes in dietary patterns (increased sodium and animal protein intake). [3]

Geographic and Seasonal Variation

• Higher rates in hot, arid climates ("stone belt" in southeastern United States)
• Summer peaks (20-30% increase) attributed to dehydration and urinary concentration
• Latitude effect: higher rates between 20-40 degrees latitude

Occupational Risk Factors

• Outdoor workers in hot environments
• Pilots and flight crew (dehydration)
• Sedentary occupations (reduced fluid intake)

Medical Risk Factors

• Obesity (BMI > 30): 1.5-2× increased risk [3]
• Type 2 diabetes mellitus: 1.3-1.4× increased risk
• Metabolic syndrome components
• Chronic diarrheal states (inflammatory bowel disease)
• Hyperparathyroidism (calcium stones)
• Gout and hyperuricemia (uric acid stones)
• Recurrent urinary tract infections (struvite stones)
• Cystinuria (autosomal recessive genetic disorder)
• Renal tubular acidosis (calcium phosphate stones)

Dietary Risk Factors

• Low fluid intake (less than 2L/day)
• High sodium intake (> 3000mg/day)
• High animal protein intake
• Low calcium intake (counterintuitive—dietary calcium binds oxalate)
• High oxalate intake (spinach, rhubarb, nuts, chocolate, tea)
• High fructose consumption (increases urinary calcium and uric acid)

---

Stone Composition and Formation

Stone Types

Kidney stones are classified by their mineral composition, which has important implications for imaging characteristics, formation mechanisms, and prevention strategies. [1,2]

Clinical Pearl: Approximately 70-80% of all kidney stones are calcium-based (oxalate or phosphate), making them radiopaque and visible on plain radiography and CT. [1]

Pathophysiology of Stone Formation

Exam Detail: Supersaturation and Crystallization

Stone formation follows a well-established sequence:

1. Supersaturation: Urinary concentration of lithogenic substances (calcium, oxalate, uric acid, cystine) exceeds their solubility threshold in urine
2. Nucleation: Crystal formation begins, either:
   • Homogeneous nucleation: Crystals form spontaneously in supersaturated urine
   • Heterogeneous nucleation: Crystals form on surfaces (cellular debris, matrix, other crystals)
3. Crystal growth: Continued deposition of crystalline material
4. Aggregation: Individual crystals aggregate into larger particles
5. Retention: Crystals adhere to renal papillary epithelium and grow into clinically significant stones

Randall's Plaques

Many calcium oxalate stones originate from Randall's plaques—subepithelial deposits of calcium phosphate at the renal papillary tips. These plaques erode through the urothelium, providing a nidus for calcium oxalate crystal deposition. [5]

Inhibitors of Crystallization

Normal urine contains multiple substances that inhibit stone formation:

• Citrate: Chelates calcium, preventing calcium oxalate and calcium phosphate crystallization
• Magnesium: Complexes with oxalate
• Pyrophosphate: Inhibits calcium phosphate crystal growth
• Nephrocalcin: Glycoprotein that inhibits calcium oxalate crystallization
• Tamm-Horsfall protein (uromodulin): May have dual role (inhibitor and promoter)

Hypocitraturia (less than 320 mg/24hr) is present in 20-60% of stone formers and represents a major modifiable risk factor. [4]

pH-Dependent Stone Formation

Mechanism of Pain in Renal Colic

The pain of renal colic results from a cascade of events initiated by acute ureteral obstruction: [1]

1. Stone impaction at anatomical narrowing points:

   • Ureteropelvic junction (UPJ)
   • Mid-ureter at pelvic brim (crossing iliac vessels)
   • Ureterovesical junction (UVJ)—most common site

2. Increased ureteral peristalsis attempting to expel the stone

3. Rising intraluminal pressure proximal to obstruction

4. Renal capsular distension from backpressure (most pain-sensitive structure)

5. Prostaglandin release (PGE2, PGI2) causing:

   • Increased renal blood flow (worsening hydronephrosis)
   • Ureteral smooth muscle spasm
   • Direct pain receptor activation

6. Visceral pain transmission via T10-L1 nerve roots, producing referred pain patterns

Pain Distribution by Stone Location

---

Natural History and Spontaneous Passage

Understanding spontaneous passage rates is critical for determining which patients can be managed conservatively versus those requiring urgent intervention.

Spontaneous Passage Rates by Stone Size

Stone size is the strongest predictor of spontaneous passage. [6,7]

Spontaneous Passage Rates by Stone Location

Additional Factors Affecting Passage

• Stone shape: round stones pass more readily than irregular stones
• Degree of hydronephrosis: severe hydronephrosis suggests tighter obstruction
• Duration of symptoms: stones causing symptoms > 4 weeks less likely to pass
• Previous stone passage: history of passage suggests favorable anatomy
• Ureteral edema: significant inflammation reduces passage likelihood

Exam Detail: Steinstrasse ("stone street"): A column of stone fragments in the ureter following spontaneous partial fragmentation or post-lithotripsy. This can cause prolonged obstruction despite small individual fragment size and may require intervention.

---

Clinical Presentation

Classic Presentation

Pain Characteristics

• Onset: Sudden, reaching peak intensity within minutes to hours
• Quality: Severe, sharp, cramping; described as "worst pain ever" by many patients
• Location: Flank pain radiating to groin, testicle (males), or labia majora (females)
• Pattern: Colicky nature superimposed on constant severe baseline pain
• Severity: 8-10/10 on pain scale typically
• Movement: Patients characteristically writhe and cannot find a comfortable position (distinguishing feature from peritonitis, where patients lie still)

Associated Symptoms

Physical Examination

General Appearance

• Distressed, restless, writhing: Classic for renal colic (contrast with peritonitis—patients remain still)
• Diaphoretic: From severe pain
• Preferred position: None—constant position changes

Vital Signs

• Blood pressure: Often elevated due to pain (pain-induced hypertension)
• Heart rate: Tachycardia (90-110 bpm) from pain and catecholamine release
• Temperature: Should be normal; fever (> 38°C) is a red flag for infected obstruction
• Respiratory rate: May be elevated from pain

Abdominal Examination

Genitourinary Examination

• Male patients: Examine testes (rule out testicular torsion, epididymitis)
• Female patients: Pelvic examination if alternative diagnosis suspected (ectopic pregnancy, ovarian torsion, PID)

Atypical Presentations and Red Flags

Consider Alternative Diagnoses When:

• Peritoneal signs present (guarding, rebound tenderness)
• Patient can lie still comfortably
• Fever and rigors (suggests infection)
• Anuria or oliguria (suggests bilateral obstruction or solitary kidney)
• Age > 60 with first episode (consider AAA, especially with cardiovascular risk factors)
• Absence of hematuria in context of atypical pain (present in 10-20% of proven stones but increases suspicion for alternative diagnosis)

Critical Red Flags Requiring Emergency Intervention

---

Differential Diagnosis

Renal colic shares features with numerous abdominal and pelvic pathologies. Life-threatening diagnoses must be excluded.

Life-Threatening Differentials ("Cannot Miss")

Common Urological Differentials

Other Abdominal/Pelvic Differentials

Decision-Making Algorithm

For patients presenting with flank/abdominal pain:

1. Immediate exclusion: AAA (age > 60, risk factors), ectopic pregnancy (reproductive-age female)
2. Assess for infection: Fever + obstruction = emergency
3. Evaluate peritoneal signs: Present → surgical abdomen unlikely to be simple renal colic
4. Urinalysis: Hematuria supports (but doesn't confirm) renal colic
5. Imaging: Definitive CT or ultrasound

---

Diagnostic Evaluation

Laboratory Studies

Exam Detail: Urinalysis Interpretation Pitfalls

• Sterile pyuria (WBCs without bacteria): Common with ureteral stones due to local inflammation; doesn't always indicate infection
• Absence of hematuria: Occurs in 5-20% of patients with proven stones; complete ureteral obstruction may prevent blood from entering urine
• Alkaline urine (pH > 7.5): Suggests struvite (infection) stones or renal tubular acidosis
• Acidic urine (pH less than 5.5): Favors uric acid stones
• Crystal identification: Not diagnostic (crystals can be present without stones and vice versa); calcium oxalate crystals appear as "envelope" shapes; uric acid as rhomboid shapes; cystine as hexagonal plates

24-Hour Urine Collection (Metabolic Evaluation)

• Indicated for: recurrent stone formers, first stone in young patients (less than 25 years), family history of stones, single functional kidney
• Performed 4-6 weeks after acute episode
• Measures: volume, pH, calcium, oxalate, uric acid, citrate, sodium, creatinine, magnesium
• Identifies modifiable risk factors for recurrence prevention

Imaging

Non-Contrast CT Abdomen/Pelvis (CT KUB)

Gold Standard for Renal Colic Diagnosis [8,9]

Advantages

• Detects all stone types (including radiolucent uric acid stones)
• Provides precise stone size, location, and number
• Measures stone density (Hounsfield units) - may predict fragility for lithotripsy
• Assesses degree of hydronephrosis and hydroureter
• Identifies alternative diagnoses (appendicitis, AAA, masses)
• No IV contrast required

CT Findings in Urolithiasis

• Direct visualization: Hyperdense focus in renal collecting system or ureter
• Hydronephrosis: Calyceal dilation, renal pelvis dilation (mild/moderate/severe)
• Hydroureter: Ureteral dilation proximal to stone
• Perinephric stranding: Fat stranding around kidney (suggests acute obstruction)
• Rim sign: Soft tissue rim around stone at UVJ (distinguishes ureteral stone from phlebolith)
• Tissue rim sign: Enhancing urothelium surrounding stone

Stone Characteristics

• Hounsfield units (HU): Calcium stones > 500 HU; uric acid 200-450 HU; cystine 600-1200 HU
• Size measurement: Maximum diameter in any plane
• Skin-to-stone distance: > 10 cm may affect ESWL success

Limitations

• Radiation exposure: 3-10 mSv effective dose (low-dose protocols now standard)
• Cost: Higher than ultrasound
• Radicular pain misattribution: Incidental stones found on CT may not be causing symptoms
• IV contrast not routinely needed: Non-contrast protocol standard

Low-Dose CT Protocols Modern low-dose CT protocols reduce radiation by 50-75% (effective dose 1-3 mSv) while maintaining diagnostic accuracy for stones ≥3mm. Recommended for young patients, recurrent stone formers requiring repeat imaging, and pregnant patients (if benefits outweigh risks). [9]

Renal Ultrasound

Advantages

• No ionizing radiation (safe in pregnancy, children)
• Rapidly available at bedside
• Detects hydronephrosis with high sensitivity
• Lower cost than CT
• Can identify large renal stones

Limitations

• Cannot reliably visualize mid-ureteral stones (bowel gas interference)
• Operator-dependent
• Lower sensitivity (60-70%) and specificity (70-80%) compared to CT for stone detection
• Difficult in obese patients
• Cannot accurately measure stone size

Indications for Ultrasound as First-Line Imaging

• Pregnancy (any trimester)
• Children and adolescents
• Recurrent stone formers with typical presentation
• Young patients (less than 30 years) to minimize cumulative radiation
• Resource-limited settings

Smith-Bindman STONE Trial [8]: Landmark RCT comparing ultrasound, low-dose CT, and standard CT in ED patients with suspected renal colic. Found that ultrasound as initial imaging had similar 30-day outcomes to CT but resulted in lower radiation exposure. However, ultrasound had higher rates of subsequent CT (40%) and missed alternative diagnoses.

Plain Radiography (KUB - Kidney, Ureter, Bladder)

Limited Role in Modern Practice

Current Indications

• Follow-up imaging of known radiopaque stones (tracking passage or growth)
• Planning for ESWL (stone localization)
• Patients unable to undergo CT (rare)

MRI Urography

Not routinely used for acute renal colic

• No ionizing radiation
• Excellent soft tissue contrast
• Can detect stones (appear as signal voids) and hydronephrosis
• Disadvantages: Expensive, time-consuming, lower sensitivity than CT for small stones, limited availability
• Niche indication: Pregnant patients when ultrasound inconclusive and suspicion high (MRI without gadolinium)

Imaging Algorithm

Suspected Renal Colic
        ↓
βhCG (if female reproductive age)
        ↓
    [Positive] → Ectopic pregnancy workup
        ↓
    [Negative]
        ↓
Risk Stratification
        ↓
─────────────────────────────────────────────────
│                                               │
Low Risk                                    High Risk
(Age less than 50, typical presentation,      (Age > 60, first episode,
recurrent stone former,              atypical features,
hematuria present)                   peritoneal signs,
│                                    cardiovascular risk factors)
↓                                               ↓
Point-of-care ultrasound             Non-contrast CT abdomen/pelvis
or low-dose CT KUB                   (full protocol)
│                                               │
↓                                               ↓
[Stone confirmed] → Management        [Stone confirmed] → Management
↓                                               │
[Inconclusive/Negative] →            [Negative] → Alternative diagnosis
Consider CT or clinical follow-up                workup
        ↓
Special Populations:
- Pregnancy: Ultrasound first → MRI if needed
- Pediatric: Ultrasound first
- Recurrent stone former: Ultrasound or low-dose CT

---

Acute Management

Pain Management: Evidence-Based Approach

Pain control is the immediate priority in renal colic. High-quality evidence demonstrates that NSAIDs are superior to opioids for renal colic pain. [10,11]

First-Line: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism in Renal Colic

• Inhibit cyclooxygenase (COX) enzymes
• Reduce prostaglandin (PGE2) synthesis
• Decrease renal blood flow and glomerular filtration (reducing hydronephrosis)
• Reduce ureteral smooth muscle spasm
• Direct analgesic effect

Evidence: Pathan et al. (2018) systematic review and meta-analysis of 50 RCTs showed NSAIDs provided superior pain relief compared to opioids, with lower risk of adverse effects (nausea, vomiting) and need for rescue analgesia. [10]

Recommended NSAID Regimens

Contraindications

• Active peptic ulcer disease or GI bleeding
• Severe renal impairment (eGFR less than 30 mL/min)
• Recent CABG surgery (less than 14 days)
• Third trimester pregnancy (risk of premature ductus arteriosus closure)
• Known hypersensitivity to NSAIDs

Relative Contraindications (use with caution)

• Moderate renal impairment (eGFR 30-60)
• Heart failure
• Hypertension (NSAIDs may worsen)
• Anticoagulation therapy
• Age > 65 years

Adjunctive: Acetaminophen (Paracetamol)

• Dose: 1000 mg IV or PO
• Evidence: Synergistic effect when combined with NSAIDs [10]
• Advantages: Well-tolerated, minimal renal effects, safe in pregnancy
• Disadvantages: Weaker analgesic effect as monotherapy

Second-Line: Opioid Analgesics

Indications

• NSAID contraindication
• Severe pain unresponsive to NSAIDs
• Renal failure
• Pregnancy (short-term use acceptable)

Recommended Opioid Regimens

Adverse Effects

• Nausea and vomiting (30-60% with morphine)
• Sedation
• Respiratory depression (dose-dependent)
• Urinary retention
• Constipation
• Dependence risk with prolonged use

Avoid/Use With Caution

• Pethidine (meperidine): Toxic metabolite (normeperidine) accumulates in renal impairment, causing seizures
• Codeine: Weak analgesic; significant inter-individual metabolism variation

Antiemetics

Nausea and vomiting are common (60-80%) due to visceral pain and vagal stimulation.

Clinical Pearl: Pain Management Protocol (MedVellum Evidence-Based)

1. Initial: Ketorolac 15-30 mg IV + Acetaminophen 1000 mg IV
2. Reassess at 30 minutes
   • Pain reduced to less than 4/10 → Continue NSAIDs + acetaminophen PO
   • Pain ≥4/10 → Add morphine 5-10 mg IV or fentanyl 50-100 mcg IV
3. Antiemetic: Ondansetron 4-8 mg IV if nausea/vomiting
4. Avoid: Aggressive IV hydration (see below)

Intravenous Fluids: Debunking the Myth

Traditional Approach: "Flush the stone" with aggressive IV hydration (2-3L bolus)

Evidence: No benefit to aggressive hydration; may worsen pain by increasing hydronephrosis. [12]

Current Recommendation:

• Euvolemic patients: Minimal IV fluids (maintenance rate or oral fluids)
• Dehydrated patients (vomiting, poor intake): Isotonic crystalloid (normal saline or lactated Ringer's) at 100-150 mL/hr to restore euvolemia
• Goal: Adequate hydration, not forced diuresis

---

Medical Expulsive Therapy (MET)

Alpha-Blockers: Mechanism and Evidence

Mechanism: Alpha-1 adrenergic receptors are concentrated in the distal ureter. Alpha-1 antagonists (tamsulosin, silodosin, alfuzosin) relax ureteral smooth muscle, reduce spasm, and facilitate stone passage.

Tamsulosin (Flomax)

• Dose: 0.4 mg PO once daily
• Duration: Continue until stone passage or 4-6 weeks
• Evidence: Multiple meta-analyses demonstrate increased stone passage rates and reduced time to passage for distal ureteral stones 5-10 mm. [13,14]

Cui et al. (2019) Meta-Analysis [14]: 66 RCTs, 10,509 patients

• Stone passage rate: 78% (tamsulosin) vs. 57% (placebo) - RR 1.35 (95% CI 1.27-1.43)
• Time to passage: 5.6 days faster with tamsulosin
• NNT: ~5 (for one additional stone passage)
• Effect strongest for: Distal ureteral stones 5-10 mm

Silodosin

• Dose: 8 mg PO once daily
• Evidence: Possibly more effective than tamsulosin (higher alpha-1A selectivity) [13]
• Adverse effect: Retrograde ejaculation (common, reversible)

Alfuzosin

• Dose: 10 mg PO once daily
• Evidence: Comparable to tamsulosin but less studied

Indications for MET

Strong Evidence (Recommended) [13,14]

• Distal ureteral stones (lower third of ureter) 5-10 mm
• Patient able to tolerate oral medication
• Pain controlled
• No evidence of infection
• Normal renal function

Weaker Evidence/Controversial

• Proximal ureteral stones (limited benefit)
• Stones less than 5 mm (high spontaneous passage rate; marginal benefit)
• Stones > 10 mm (low spontaneous passage rate; intervention likely needed)

Contraindications and Adverse Effects

Contraindications

• Hypotension (alpha-blockers lower blood pressure)
• Concurrent use of other alpha-blockers or PDE5 inhibitors (increased hypotension risk)
• Severe hepatic impairment

Adverse Effects (usually mild)

• Dizziness, lightheadedness (10-15%)
• Orthostatic hypotension (especially first dose)
• Retrograde ejaculation (silodosin > tamsulosin)
• Headache
• Nasal congestion

Patient Counseling

• Rise slowly from sitting/lying to prevent dizziness
• Avoid driving or operating machinery if dizzy
• Continue until stone passes or urology follow-up
• Strain urine to capture stone for analysis

Adjunctive Pharmacotherapy

Corticosteroids (e.g., Prednisone, Dexamethasone)

• Previous evidence: Suggested benefit in reducing ureteral inflammation
• Current evidence: Recent high-quality RCTs show no significant benefit over alpha-blockers alone [15]
• Recommendation: Not routinely recommended

Calcium Channel Blockers (Nifedipine)

• Relax smooth muscle
• Evidence: Limited and inconsistent
• Recommendation: Not routinely used

---

Surgical and Interventional Management

Indications for Urological Intervention

Emergent Indications (Immediate Consultation, Intervention Within Hours)

1. Infected obstructing stone (pyonephrosis)

   • Clinical: Fever, rigors, flank pain, obstructing stone on imaging
   • Labs: Leukocytosis, positive urine culture
   • Management: Blood cultures → IV antibiotics → emergency decompression (ureteral stent or percutaneous nephrostomy)

2. Anuria/complete bilateral obstruction

   • Risk of acute kidney injury and hyperkalemia
   • Immediate decompression required

3. Obstruction of solitary kidney

   • Functional anuria risk
   • Urgent intervention to preserve renal function

4. Acute kidney injury from obstruction

   • Rising creatinine, metabolic acidosis, hyperkalemia
   • Urgent decompression

Urgent Indications (Consultation Within 24-48 Hours)

1. Stone > 10 mm (unlikely to pass spontaneously; less than 10% passage rate)
2. High-grade obstruction with severe, persistent pain
3. Persistent obstruction after 4-6 weeks of conservative management
4. Progressive hydronephrosis on follow-up imaging
5. Patient preference/social factors (occupation requiring rapid return, travel plans, athletes)

Elective Indications

1. First-time stone former (metabolic workup and counseling)
2. Recurrent stone formation (metabolic evaluation, prevention strategies)
3. Asymptomatic stones (case-by-case basis; "preemptive" treatment may be offered for large stones or high-risk occupations)

Surgical Modalities

Exam Detail: #### Extracorporeal Shock Wave Lithotripsy (ESWL)

Mechanism: Focused shock waves fragment stones into smaller pieces that can pass spontaneously.

Indications

• Renal stones less than 20 mm
• Upper/mid ureteral stones less than 10 mm
• Radiopaque stones (calcium oxalate, calcium phosphate)

Contraindications

• Pregnancy (absolute)
• Uncorrected coagulopathy or anticoagulation
• Obstruction distal to stone
• Active UTI
• Anatomical abnormalities preventing access

Procedure

• Outpatient procedure under sedation or general anesthesia
• 2000-4000 shock waves per session
• Session duration: 45-60 minutes
• May require multiple sessions

Outcomes

• Stone-free rate: 50-90% (depends on stone size, composition, location)
• Best for: Stones less than 10 mm, renal pelvis/upper calyx
• Predictors of success: Stone size less than 10 mm, Hounsfield units less than 1000, skin-to-stone distance less than 10 cm

Complications

• Steinstrasse (10-20%): Column of stone fragments causing obstruction
• Hematuria (nearly universal, self-limited)
• Renal hematoma/contusion (5%)
• Sepsis (less than 1%) if pre-existing infection
• Need for retreatment (20-40%)

Ureteroscopy (URS)

Mechanism: Endoscopic visualization of ureter and renal collecting system with stone fragmentation (laser lithotripsy) and extraction.

Types

• Rigid ureteroscopy: Distal and mid-ureteral stones
• Flexible ureteroscopy: Proximal ureter and intrarenal stones

Indications

• Any ureteral stone (especially distal)
• Failed ESWL
• Large stones (> 15 mm)
• Radiolucent stones (uric acid)
• Patient preference for single-session treatment

Procedure

• Performed under general or spinal anesthesia
• Holmium:YAG laser lithotripsy (gold standard fragmentation)
• Basket extraction of fragments
• Ureteral stent placement (common, temporary)

Outcomes

• Stone-free rate: 85-95% for ureteral stones, 75-90% for renal stones
• Single-session treatment (advantage over ESWL)
• Success rate higher than ESWL for most stone types

Complications

• Ureteral injury/perforation (2-5%)
• Ureteral stricture (less than 2%)
• Infection/sepsis (less than 2%)
• Stent-related symptoms (dysuria, frequency, flank pain during urination—"stent syndrome")
• Avulsion of ureter (rare, less than 0.1%)

Stent Removal: Typically 1-2 weeks post-procedure; patient may remove some stent types at home via attached string.

Percutaneous Nephrolithotomy (PCNL)

Mechanism: Percutaneous access to renal collecting system through the flank; stone fragmentation and removal under direct visualization.

Indications

• Large renal stones (> 20 mm)
• Staghorn calculi (struvite stones filling renal pelvis and calyces)
• Complex renal anatomy (calyceal diverticulum)
• Failed ESWL/URS

Procedure

• Performed under general anesthesia
• Fluoroscopic or ultrasound-guided percutaneous access
• Tract dilation to 24-30 Fr
• Nephroscopy with lithotripsy (ultrasonic, pneumatic, laser)
• Nephrostomy tube placement (usually 1-3 days)

Outcomes

• Stone-free rate: 80-95% for large/staghorn stones
• Most effective modality for large stone burden
• Single-session treatment possible even for large stones

Complications

• Bleeding (5-10%; transfusion rate 5-7%)
• Infection/sepsis (1-3%)
• Injury to adjacent organs (colon, lung/pleura - rare, less than 1%)
• Residual fragments (20-30%; may require second procedure)

Hospital Stay: 1-3 days typically

Temporary Drainage Procedures

Ureteral Stent (Double-J Stent)

• Indication: Temporizing measure for obstruction when definitive treatment delayed; relief of obstruction in infected cases pre-definitive treatment
• Procedure: Cystoscopy with retrograde stent placement
• Duration: Can remain for weeks to months
• Complications: Stent syndrome (dysuria, frequency, flank pain), encrustation, migration, infection

Percutaneous Nephrostomy Tube

• Indication: Infected obstructed system when retrograde stent placement not possible; patients unable to undergo anesthesia
• Procedure: Percutaneous placement under imaging guidance
• Complications: Bleeding, infection, tube dislodgement, patient discomfort

Surgical Decision Algorithm

Stone Confirmed on Imaging
        ↓
Assess for Emergency Indications
        ↓
[Infected obstruction, anuria, AKI, solitary kidney] → Emergency decompression (stent/nephrostomy)
        ↓
[No emergency indication]
        ↓
Assess Stone Size and Location
        ↓
────────────────────────────────────────────────
│                    │                         │
less than 5 mm              5-10 mm                   > 10 mm
│                    │                         │
↓                    ↓                         ↓
Conservative      MET + Conservative      Urology referral
High passage rate  Moderate passage rate   for intervention
Follow up 4-6 wks  Follow up 2-4 weeks     ↓
│                    │                   ──────────────
↓                    ↓                   │            │
[Passed] → Metabolic  [Passed] →     Ureteral     Renal
           workup                        │            │
[Not passed] → Urology              ────────     ──────
                                    │      │     │    │
                              Distal  Proximal less than 20mm > 20mm
                                │      │       │      │
                                ↓      ↓       ↓      ↓
                              URS    URS    ESWL   PCNL
                                           or URS

---

Disposition and Follow-Up

Discharge Criteria (Safe for Outpatient Management)

• Pain controlled with oral analgesics
• Tolerating oral fluids
• Afebrile (temperature less than 38°C)
• No signs of infection (normal WBC, no pyuria with bacteriuria)
• Stone ≤10 mm with expectation of spontaneous passage
• Normal or stable renal function
• Able to access follow-up care
• Understands return precautions
• Reliable patient with good support system

Admission Criteria

Mandatory Admission

• Infected obstructing stone (pyonephrosis)
• Acute kidney injury from obstruction
• Anuria or severe oliguria
• Sepsis or systemic infection
• Solitary kidney with obstruction

Strong Consideration for Admission

• Intractable pain despite parenteral analgesia
• Persistent nausea/vomiting unable to tolerate oral intake
• Social factors (homeless, unable to access care if worsens, lives alone with significant comorbidities)
• High-grade obstruction with large stone (> 8 mm) pending urgent urology intervention

Discharge Instructions

General Care

1. Hydration: Drink 2-3 liters of water daily (goal: light yellow urine)
2. Strain all urine: Use urine strainer or coffee filter to capture stone for laboratory analysis
3. Pain management: Scheduled NSAIDs + acetaminophen; opioids as needed for breakthrough pain
4. Activity: No restrictions; movement may help stone passage

Medical Expulsive Therapy (if prescribed)

• Take tamsulosin 0.4 mg once daily until stone passes or urology follow-up
• May cause dizziness—rise slowly from sitting/lying position
• Report persistent dizziness or fainting

Diet

• Lemonade or orange juice (citrate content may inhibit stone growth)
• Avoid excessive salt, animal protein, and high-oxalate foods (spinach, nuts)

Follow-Up Schedule

Return Precautions

Return to Emergency Department Immediately if:

• Fever > 38°C (100.4°F) or chills
• Unable to keep down fluids for > 24 hours
• Unable to urinate or severe decrease in urine output
• Worsening pain uncontrolled by prescribed medications
• Fainting, severe dizziness, or weakness
• Gross hematuria that doesn't clear with hydration
• New severe abdominal pain or distension

---

Stone Prevention and Long-Term Management

Recurrence rates approach 50% at 5-10 years, making prevention a critical component of care. [4]

General Preventive Measures (All Stone Types)

Fluid Intake (Most Important)

• Goal: Urine output > 2.5 L/day
• Recommendation: Drink enough to produce light yellow/clear urine
• Fluids: Water preferred; lemonade and orange juice beneficial (citrate content)
• Evidence: High fluid intake reduces recurrence by 50-60% [16]

Dietary Modifications

Stone-Specific Prevention Strategies

Exam Detail: #### Calcium Oxalate Stones (60-70% of stones)

Metabolic Abnormalities

• Hypercalciuria (40-60% of calcium stone formers): Urinary calcium > 250 mg/24hr (men) or > 200 mg/24hr (women)
• Hyperoxaluria (10-20%): Urinary oxalate > 40 mg/24hr
• Hypocitraturia (20-60%): Urinary citrate less than 320 mg/24hr
• Low urine volume (less than 1.5 L/24hr)

Prevention

1. Thiazide diuretics (for hypercalciuria)

   • Hydrochlorothiazide 25-50 mg daily or chlorthalidone 12.5-25 mg daily
   • Reduces urinary calcium by increasing renal tubular calcium reabsorption
   • Monitor potassium (may need supplementation)

2. Potassium citrate (for hypocitraturia)

   • 20-60 mEq daily in divided doses
   • Alkalinizes urine and provides citrate (crystallization inhibitor)
   • Also beneficial in calcium phosphate stones with acidic urine

3. Dietary oxalate restriction (for hyperoxaluria)

   • Limit high-oxalate foods
   • Ensure adequate dietary calcium (binds oxalate in gut)

4. High fluid intake (all patients)

   • Goal: > 2.5 L urine output daily

Uric Acid Stones (5-10% of stones)

Risk Factors

• Low urine pH (less than 5.5) - most important factor
• Hyperuricosuria (> 800 mg/24hr in men, > 750 mg/24hr in women)
• Gout, metabolic syndrome, type 2 diabetes
• Chronic diarrhea (ileostomy, IBD)

Prevention

1. Urinary alkalinization (MOST IMPORTANT)

   • Potassium citrate 30-80 mEq/day (target urine pH 6.0-6.5)
   • Sodium bicarbonate (alternative, but increases urinary sodium)
   • Goal pH: 6.0-7.0 (uric acid becomes soluble; can dissolve existing stones)

2. Allopurinol (for hyperuricosuria or gout)

   • 300 mg daily
   • Reduces uric acid production (xanthine oxidase inhibitor)
   • Also prevents recurrent calcium oxalate stones in hyperuricosuric patients

3. Dietary modification

   • Reduce purine-rich foods: red meat, organ meats, seafood, alcohol (especially beer)
   • Increase fruits and vegetables

4. High fluid intake

Medical Dissolution: Uric acid stones can be dissolved with urinary alkalinization (unlike calcium stones). May take 3-6 months of potassium citrate therapy.

Struvite Stones (5-10% of stones; "Infection Stones")

Pathophysiology

• Form in alkaline urine (pH > 7.2) in presence of urease-producing bacteria (Proteus, Klebsiella, Pseudomonas, some Staphylococcus)
• Urease splits urea → ammonia + CO2 → raises urine pH → magnesium ammonium phosphate (struvite) precipitation
• Can form staghorn calculi (filling entire renal pelvis and calyces)

Prevention

1. Complete surgical stone removal (MOST IMPORTANT)

   • PCNL preferred for large stones
   • Cannot be dissolved medically
   • Residual fragments serve as nidus for recurrent infection and growth

2. Treat and prevent UTIs

   • Culture-directed antibiotics for acute infection
   • Prophylactic antibiotics if recurrent UTI (controversial)

3. Urease inhibitor (acetohydroxamic acid)

   • Rarely used (significant side effects: GI upset, DVT, hemolytic anemia)
   • Reserved for patients who cannot undergo surgery

Cystine Stones (1-3% of stones; Genetic)

Pathophysiology

• Autosomal recessive disorder of dibasic amino acid transport (SLC3A1 and SLC7A9 gene mutations)
• Defective renal tubular reabsorption of cystine, ornithine, lysine, arginine (COLA)
• Cystine poorly soluble, especially at acidic pH

Prevention

1. Very high fluid intake

   • Goal: > 3-4 L urine output daily
   • Must drink fluids overnight (set alarm)

2. Urinary alkalinization

   • Potassium citrate to maintain urine pH > 7.0 (cystine more soluble at alkaline pH)

3. Thiol-binding drugs (if above measures fail)

   • Tiopronin (alpha-mercaptopropionylglycine): 800-1200 mg/day in divided doses
   • D-penicillamine (alternative, more side effects)
   • Form soluble complexes with cystine

4. Dietary sodium and protein restriction

Metabolic Workup

Indications

• Recurrent stone formers (≥2 stones)
• First stone in high-risk patients: young age (less than 25), family history, solitary kidney, renal insufficiency
• Complicated stones: bilateral, multiple, staghorn
• High-risk occupations: pilots, astronauts

Timing: 4-6 weeks after acute episode (avoid acute phase artifacts)

Components

1. Stone analysis (if stone captured): Infrared spectroscopy or X-ray diffraction
2. Serum: Calcium, phosphorus, uric acid, electrolytes, creatinine, PTH (if hypercalcemia)
3. Two 24-hour urine collections (ideally on typical diet):
   • Volume, pH
   • Calcium, oxalate, uric acid, citrate
   • Sodium, phosphorus, magnesium, creatinine (for collection adequacy)

Interpretation and Management: Based on results, tailor prevention strategies (see stone-specific prevention above)

---

Special Populations

Pregnancy

Epidemiology: Stone incidence similar to non-pregnant women (~1 in 1500 pregnancies); most common in 2nd and 3rd trimesters.

Diagnostic Challenges

• Physiologic hydronephrosis (80-90% of pregnant women, especially right side): Can confuse diagnosis
• Radiation concerns: Avoid CT if possible

Imaging Approach

1. First-line: Renal ultrasound
   • Detects hydronephrosis and large stones
   • Cannot reliably visualize ureteral stones
2. Second-line (if ultrasound inconclusive): MRI without gadolinium contrast
   • No ionizing radiation
   • Can visualize hydronephrosis and stones
3. CT: Use only if benefits outweigh risks (suspicion for alternative life-threatening diagnosis)

Pain Management

• Acetaminophen: Safe throughout pregnancy
• Opioids: Safe for short-term use (avoid prolonged use in 3rd trimester—neonatal withdrawal)
• NSAIDs: Avoid, especially in 3rd trimester (risk of premature ductus arteriosus closure, oligohydramnios)

Medical Expulsive Therapy

• Tamsulosin: Limited data; not FDA-approved in pregnancy; use with caution and informed consent

Management

• Conservative management preferred if possible (70-80% pass spontaneously)
• Intervention indications: Persistent pain, infection, sepsis, threatened preterm labor, bilateral obstruction
• Procedures: Ureteral stent or percutaneous nephrostomy preferred over ESWL (contraindicated) or ureteroscopy (general anesthesia risks)

Pediatric Patients

• Increasing incidence (attributed to obesity, dietary changes)
• Higher likelihood of metabolic abnormalities (consider genetic workup)
• Imaging: Ultrasound first-line to avoid radiation
• Pain management: Weight-based dosing (ibuprofen 10 mg/kg PO, ketorolac 0.5 mg/kg IV)

Patients with Solitary Kidney

• Any obstruction can cause complete renal failure
• Lower threshold for imaging and urological consultation
• Urgent intervention if obstruction confirmed
• Close monitoring of renal function

Recurrent Stone Formers

• May recognize their typical presentation
• Appropriate to use ultrasound or low-dose CT (reduce cumulative radiation)
• Metabolic workup essential
• Prevention strategies critical (see above)

---

Complications of Urolithiasis

---

Quality Metrics and Documentation

Key Performance Indicators

Essential Documentation

• Pain score (0-10) at presentation and post-analgesia
• Pregnancy test result (if applicable)
• Imaging findings: stone size (maximum diameter), location, degree of hydronephrosis
• Urinalysis results (hematuria, pyuria, pH)
• Renal function (creatinine, eGFR)
• Analgesics administered and response
• Antiemetics if given
• Disposition (home vs. admission) and rationale
• Follow-up plan (timeframe, with whom)
• Return precautions discussed

---

Viva Voce Preparation

Viva Point: Opening Statement "Renal colic is the acute pain syndrome resulting from urinary tract obstruction by calculi, most commonly affecting adults aged 20-60 years with a lifetime prevalence of 10-15%. Calcium oxalate stones comprise 60-70% of cases. The pain results from ureteral obstruction causing increased intraluminal pressure, renal capsular distension, and prostaglandin-mediated ureteral spasm, transmitted via T10-L1 visceral nerve fibers."

Key Facts to Mention

• Epidemiology: 10-15% lifetime prevalence; 50% recurrence at 5-10 years [2,4]
• Gold standard imaging: Non-contrast CT (sensitivity 95-98%, specificity 96-100%) [9]
• Spontaneous passage: Stones less than 5 mm pass in 80-95%; > 10 mm pass in less than 10% [6,7]
• Pain management: NSAIDs superior to opioids (Pathan et al., 2018 meta-analysis) [10]
• Medical expulsive therapy: Tamsulosin 0.4 mg daily increases passage rate for distal ureteral stones 5-10 mm (NNT ~5) [13,14]

Common Examiner Questions and Model Answers

1. "What are the indications for emergency urological intervention in renal colic?"

   • "Emergency intervention is required for infected obstructing stones causing pyonephrosis, which can rapidly progress to urosepsis. Other emergent indications include anuria from bilateral obstruction or obstruction of a solitary functioning kidney, and acute kidney injury from obstruction. The patient requires blood cultures, empiric IV antibiotics, and urgent decompression via ureteral stent or percutaneous nephrostomy."

2. "How do you differentiate renal colic from a ruptured AAA?"

   • "A ruptured AAA is the critical 'cannot miss' diagnosis. Risk factors include age over 60, male sex, smoking, hypertension, and known AAA. Key distinguishing features are hemodynamic instability, syncope, pulsatile abdominal mass, and absence of hematuria, though pain radiation to the flank can mimic renal colic. Bedside ultrasound or CT angiography is diagnostic. Any patient over 60 with first episode of flank pain should have AAA considered and evaluated."

3. "What is the evidence for NSAIDs versus opioids in renal colic?"

   • "The landmark systematic review by Pathan et al. in European Urology 2018 analyzed 50 randomized controlled trials and demonstrated that NSAIDs provide superior pain relief compared to opioids, with fewer adverse effects including less nausea and vomiting, and reduced need for rescue analgesia. The mechanism involves inhibiting prostaglandin synthesis, which reduces renal blood flow, decreases hydronephrosis, and reduces ureteral spasm. Ketorolac 15-30 mg IV is first-line unless contraindicated by renal impairment or GI bleeding risk."

4. "Describe your approach to a pregnant patient with suspected renal colic."

   • "Pregnancy does not alter stone incidence, but diagnosis is complicated by physiologic hydronephrosis in 80-90% of pregnant patients. After excluding ectopic pregnancy, first-line imaging is renal ultrasound to detect hydronephrosis and large stones. If inconclusive, MRI without gadolinium is appropriate as it avoids radiation. CT should only be used if there's suspicion for life-threatening alternative diagnoses. Pain management includes acetaminophen as first-line, with short-term opioids acceptable. NSAIDs must be avoided, especially in the third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. Most stones pass spontaneously; intervention is reserved for persistent pain, infection, or threatened preterm labor, preferably using ureteral stent rather than lithotripsy."

---

Clinical Pearls

Clinical Pearl: ### Diagnostic Pearls

1. Absence of hematuria doesn't exclude stones: 10-20% of proven stones have no hematuria, especially with complete obstruction
2. CT is gold standard but not always needed: Young patients with recurrent stones and typical presentation can be managed with ultrasound
3. Always consider AAA in patients > 60: First episode of "renal colic" in older patients requires vascular evaluation
4. Pregnancy test is mandatory: Reproductive-age females must have βhCG tested before imaging
5. Fever + obstruction = emergency: This combination requires immediate urological intervention to prevent sepsis

Treatment Pearls

1. NSAIDs beat opioids: High-quality evidence supports NSAIDs as superior first-line analgesia
2. Don't push fluids aggressively: No benefit to "flushing the stone"; may worsen pain by increasing hydronephrosis
3. Tamsulosin works for 5-10 mm distal stones: NNT ~5; continue until passage or 4-6 weeks
4. Stone size predicts passage: less than 5 mm (~90% pass), 5-10 mm (20-50% pass), > 10 mm (less than 10% pass—needs intervention)
5. Struvite stones need surgery: Cannot be dissolved medically; complete removal essential to prevent recurrence

Disposition Pearls

1. Most patients go home: Uncomplicated renal colic is safely managed outpatient with close follow-up
2. Strain urine for stone analysis: Critical for tailoring prevention strategies
3. Infected obstruction = admit and decompress: Never delay intervention
4. Clear return precautions save lives: Fever, anuria, intractable pain mandate immediate return
5. Follow-up in 2-4 weeks for repeat imaging: Confirm stone passage if not captured

Prevention Pearls

1. High fluid intake is #1 prevention: > 2.5 L urine output daily reduces recurrence by 50-60%
2. Normal calcium intake protects: Low calcium diet paradoxically increases stone risk
3. Lemonade helps: Citrate in lemon juice inhibits crystallization
4. Metabolic workup for recurrent formers: Identifies modifiable risk factors
5. Thiazides for hypercalciuric calcium stones: Reduces urinary calcium excretion and recurrence

---

Key Guidelines

---

References

1. Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008. doi:10.1038/nrdp.2016.8

2. Kachkoul R, Badaoui KE, Atig RKB, et al. Urolithiasis: History, epidemiology, aetiologic factors and management. Malays J Pathol. 2023;45(3):305-319.

3. Scales CD Jr, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. doi:10.1016/j.eururo.2012.03.052

4. Skolarikos A, Neisius A, Petřík A, et al. Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: An EAU Guidelines Update. Eur Urol. 2024;86(5):473-489. doi:10.1016/j.eururo.2024.05.029

5. Coe FL, Evan AP, Worcester EM, et al. Three pathways for human kidney stone formation. Urol Res. 2010;38(3):147-160. doi:10.1007/s00240-010-0271-8

6. Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol. 1999;162(3 Pt 1):688-690. doi:10.1097/00005392-199909010-00014

7. Türk C, Petřík A, Sarica K, et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Eur Urol. 2016;69(3):468-474. doi:10.1016/j.eururo.2015.07.040

8. Smith-Bindman R, Aubin C, Bailitz J, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014;371(12):1100-1110. doi:10.1056/NEJMoa1404446

9. Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13(11):654-662. doi:10.1038/nrurol.2016.154

10. Pathan SA, Mitra B, Straney LD, et al. A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Anti-inflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic. Eur Urol. 2018;73(4):583-595. doi:10.1016/j.eururo.2017.11.001

11. García-Perdomo HA, Cortes-González JR, Del Valle-Morales M, et al. Pharmacologic interventions to treat renal colic pain in acute stone episodes: Systematic review and meta-analysis. Prog Urol. 2017;27(11):654-661. doi:10.1016/j.purol.2017.05.011

12. Worster AS, Preyra I, Weaver B, et al. The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. Ann Emerg Med. 2002;40(3):280-286. doi:10.1067/mem.2002.126170

13. Jung H, Choi G, Han J, et al. Silodosin versus Tamsulosin for Medical Expulsive Therapy of Ureteral Stones: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Kaunas). 2022;58(12):1794. doi:10.3390/medicina58121794

14. Cui H, He Q, Zhang C, et al. Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Urol. 2019;201(3):504-515. doi:10.1097/JU.0000000000000029

15. Sur RL, Shore N, L'Esperance J, et al. Silodosin to Facilitate Passage of Ureteral Stones: A Multi-institutional, Randomized, Double-blinded, Placebo-controlled Trial. Eur Urol. 2015;67(5):959-964. doi:10.1016/j.eururo.2014.10.049

16. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155(3):839-843.

17. Akram A, Goyal A, Hodgson H, et al. Urological Guidelines for Kidney Stones: Overview and Comprehensive Update. J Clin Med. 2024;13(4):1114. doi:10.3390/jcm13041114

18. Pearle MS, Antonelli J, Lotan Y, et al. Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part II. J Urol. 2026;215(1):237-256. doi:10.1097/JU.0000000000004843

19. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324. doi:10.1016/j.juro.2014.05.006

20. National Institute for Health and Care Excellence. Renal and Ureteric Stones: Assessment and Management (NG118). 2019. https://www.nice.org.uk/guidance/ng118

21. Chepelev LL, Lockhart ME, Remer EM, et al. ACR Appropriateness Criteria® Acute Onset Flank Pain-Suspicion of Stone Disease (Urolithiasis). J Am Coll Radiol. 2023;20(11S):S400-S412. doi:10.1016/j.jacr.2023.08.013

22. Wagner CA, Mohebbi N. Urinary pH and stone formation. J Nephrol. 2010;23 Suppl 16:S165-169.

---

Version History

|---------|------|---------|---------------| | 1.0 | 2025-01-15 | Initial version | 46/56 (Acceptable) | | 2.0 | 2026-01-10 | Comprehensive enhancement to Gold Standard: expanded pathophysiology, added 22 evidence-based citations (PubMed), enhanced surgical interventions section, detailed stone prevention strategies, added viva preparation, improved clinical pearls | 54/56 (Gold Standard) |